ARMEN GARO H purchased $1K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 5,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.26 on 2026-08-05.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the executive chair’s direct open-market purchase of 5,000 shares at $0.2588 on 2026-08-05, with no pre-arranged 10b5-1 plan.
Market read
Traders may treat the filing as a small sentiment input, but it is not a fundamental catalyst.
What to watch
The filing does not disclose intent, timing constraints, or whether other insiders are buying/selling, and it provides no accompanying corporate catalyst.
Background
This is an SEC Form 4 insider transaction disclosure for Protagenic Therapeutics, Inc. (PTIX).
Ticker impact
Protagenic Therapeutics disclosed an insider open-market purchase by Executive Chair and Principal Officer Armen Garo H of 5,000 shares at $0.2588.
Near-term impact is likely limited; any effect would be sentiment-driven rather than a new fundamental catalyst.
Insider buying can signal confidence, but the filing provides no new company-specific operational or financial information, and the transaction size is modest relative to typical market-moving events.
Market effects
No clear sector read-through because the filing contains no clinical, regulatory, or financing updates.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity or diversification activity and do not necessarily imply near-term upside.
Key entities
- issuerProtagenic Therapeutics, Inc.
Company whose insider transaction was reported on Form 4 (PTIX).
- insiderArmen Garo H
Executive Chair and Principal Officer who purchased 5,000 shares directly.